True

Meyer, Tim; Rustin, G. J. S.

doi:10.1054/bjoc.2000.1174

Cited by 168 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, no objective responses were obtained but 10 women (17%) had stable disease on scan for at least 12 weeks. Using Rustin’s criteria [13, 14], the investigators observed a partial CA 125 response in 8% of patients. The tumor marker fell <50% and then remained stable in another 14 patients (23%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer

et al. 2004

View full text Add to dashboard Cite

Objective: We conducted a phase II trial to evaluate the activity of oral letrozole in women with relapsed or recurrent epithelial ovarian cancer. Methods: Twenty-seven patients were treated with letrozole at a dose of 2.5 mg once a day. Patients with measurable or evaluable disease (n = 21) and those with only increasing CA 125 serum levels (n = 6) were eligible. Paraffin-fixed histological sections from tumor specimens resected at the initial laparotomy were assessed for the presence of estrogen, and progesterone receptors. Results: Among the 21 patients with measurable or evaluable disease who were evaluated for response by WHO criteria, we observed one complete and two partial responses for an objective response rate of 15%. Using criteria for CA 125 response we obtained a marker response in 4 of 27 patients (15%), and the marker remained stable in 5 additional patients (18%). Letrozole treatment was generally well tolerated. No correlation was observed between tumor marker response or stabilization and either estrogen or progesterone receptor expression. Conclusion: The results of our study suggest that the aromatase inhibitor letrozole is an agent with some activity and limited toxicity for relapsed ovarian cancer. As we could not find any association between response and hormonal receptor expression, the underlying mechanisms of letrozole action have to be elucidated.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A 75% response occurred if there was a fall in the value of CA 125 by 75% over three samples. In each case, the final sample had to be analysed at least 28 days from the preceding sample [13, 14]. Stable value was defined as a <50% rise in the CA 125 level for at least three months.…”

Section: Methodsmentioning

confidence: 99%

Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…However, CA125 is the only currently used diagnostic biomarker for ovarian CCC. Furthermore, CA125 is also elevated in patients with endometriosis (EMS), from which CCC is thought to arise [9, 10]. Although it is very important to monitor the transformation from EMS into CCC, there is currently no biomarker that can efficiently distinguish between these diseases.…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

et al. 2016

View full text Add to dashboard Cite

BackgroundThere is currently no reliable serum biomarker for ovarian clear cell carcinoma (CCC), a highly lethal histological subtype of epithelial ovarian cancer (EOC). Previously, using a proteome-based approach, we identified tissue factor pathway inhibitor 2 (TFPI2) as a candidate serum biomarker for CCC. In this study, we sought to evaluate the clinical diagnostic performance of TFPI2 in preoperative prediction of CCC.MethodsSerum TFPI2 levels were measured in serum samples from a retrospective training set consisting of patients with benign and borderline ovarian tumors, EOC subtypes, and uterine diseases. Via receiver operating characteristic (ROC) analyses, we compared the diagnostic performance of TFPI2 with that of CA125 in discrimination of patients with ovarian CCC from other patient groups. The observed diagnostic performances were examined in a prospective validation set.ResultsThe 268-patient training set included 29 patients with ovarian CCC. Unlike CA125, which was also elevated in patients with endometriosis and several EOC subtypes, serum TFPI2 levels were specifically elevated only in ovarian CCC patients, consistent with the mRNA expression pattern in tumor tissues. The area under the ROC curve (AUC) of serum TFPI2 was obviously higher than that of CA125 for discrimination of CCC from other ovarian diseases (AUC = 0.891 versus 0.595). Applying a cut-off value of 280 pg/mL, TFPI2 could distinguish early-stage (FIGO I and II) CCC from endometriosis with 72.2% sensitivity, 93.3% specificity, and 88.8% accuracy. Similar results were confirmed in an independent 156-patient prospective validation set.ConclusionsTFPI2 is a useful serum biomarker for preoperative clinical diagnosis of CCC.

show abstract

“…7 Changes in the level of CA-125 and other laboratory workup can be used as a reliable indicator of response or progression, but these do not, yet, have a clear place in diagnosis or prognosis. 8,9 Ultrasound (US) is the first-line imaging investigation in the detection and characterization of ovarian tumours, but on the other hand, it is an operator-dependent technique, less panoramic than MRI and shows less distinction of solid soft-tissue components. 10 MRI can distinguish several types of tissue and fluid from their signal intensity (SI) patterns.…”

Section: Introductionmentioning

confidence: 99%

Semi-quantitative contrast-enhanced MR analysis of indeterminate ovarian tumours: when to say malignancy?

Mansour

Saraya

El-Faissal

2015

BJR

View full text Add to dashboard Cite

Objective: To evaluate the ability of dynamic post-contrast sequence to specify indeterminate ovarian masses with inconclusive MR features of malignancy. Since management is dramatically different, special focus on the ability to differentiate borderline from invasive malignancy was considered. Methods: 150 ovarian masses were detected by pelvic ultrasound in 124 patients. Masses had been considered for dynamic post-contrast MRI. We expressed the kinetic parameters (i.e. enhancement amplitude, time peak of maximal uptake and maximal slope) in the form of maximum relative enhancement percentage (MRE%), time of maximal peak of contrast uptake (T max ) and slope enhancement ratio (SER) curves. Histological findings were the gold standard of reference. Results: Malignant ovarian masses showed higher MRE% than benign and borderline masses (p , 0.001). T max was shorter for malignant than benign (p , 0.01) and borderline (p , 0.001) ovarian masses. SER curves were the most suggestive of malignancy with a specificity and accuracy of 85.7% and 84.7%, respectively. Conclusion: Dynamic contrast-enhanced MRI could be a specific sequence to differentiate ovarian masses with indeterminate MR morphology with a special discrimination for low potential from invasive ovarian malignancy. Advances in knowledge: The study evaluated the diagnostic performance of the individual parameters of dynamic post-contrast MR sequence in evaluating ovarian masses. Management divert between benign, borderline and invasive malignant masses; our work presented a cut-off value for the peak of contrast uptake of 120%, which helped in the differentiation between benign and malignant tumours; the SER curves with Type III (early washout) pattern that was indicative of invasive malignancy was more specific than borderline malignancy.

show abstract

True

Cited by 168 publications

References 35 publications

Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer

Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma

Semi-quantitative contrast-enhanced MR analysis of indeterminate ovarian tumours: when to say malignancy?

Contact Info

Product

Resources

About